You Position: Home > Paper
卵巢浆液性癌的两级分级系统及其临床意义
( views:250, downloads:192 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Obstetrics and Gynecology
- Issue:
- 10
- DOI:
- 10.3760/cma.j.issn.0529-567x.2011.10.005
- Key Word:
- No keyword available
Abstract： 卵巢癌病死率居妇科恶性肿瘤之首,2010年美国因卵巢癌死亡患者为13850例,尽管目前手术技巧已日臻成熟,加之铂类、紫杉醇类以及二线化疗药物的辅助应用,但30年来,卵巢癌患者的5年生存率也仅从37％提高至46％[1].卵巢浆液性癌(ovarianserous carcinoma,OSC)是卵巢癌最常见的组织学类型,近10年来,随着临床病理学和分子遗传学研究的进一步深入,由美国德州大学M.D.安德森癌症中心(The University of Texas M.D.Anderson Cancer Center,MDACC)首先提出的OSC的组织学分级——两级分级系统(two-tier grading system)已逐渐被广泛采用[2],该分级系统对OSC的发生机制、预后判断、治疗等方面具有重要的临床意义.
- [1]Chih-Yi, Hsu,Robert, Bristow,Moon Seok, Cha,etc.Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.[J].2004,10.
- [2]Elke, Jarboe,Ann, Folkins,Marisa R, Nucci,etc.Serous carcinogenesis in the fallopian tube: a descriptive classification.[J].2008,27.
- [3]Gardner GJ,Shih IM,Kim YW,etc.Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.[J].2007,17(3).
- [4]Shimizu,Y,Kamoi,S,Amada,S,etc.Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system (see comments)[J].1998,70(1).
- [5]Gershenson DM,Sun CC,Lu KH,etc.Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.[J].2006,108(2).
- [6]Iida K,Miyazaki K,Nakayama K,etc.KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.[J].2008,99(12).
- [7]Anais, Malpica,Michael T, Deavers,Carmen, Tornos,etc.Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma.[J].2007,31.
- [8]Jemal,A.,Siegel,R.,Xu,J.,etc.Cancer statistics, 2010[J].2010,60(5).
- [9]Shih IeM,Kurman RJ,Vang R.Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.[J].2009,16(5).
- [10]Shih IeM,Kurman RJ,Visvanathan K,etc.Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.[J].2008,198(4).
- [11]Saleemuddin A,Folkins AK,Garrett L,etc.Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.[J].2008,111(2).
- [12]Shaw PA,Rouzbahman M,Pizer ES.Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.[J].2009,22(9).
- [13]Ricciardelli C,Oehler MK.Diverse molecular pathways in ovarian cancer and their clinical significance.[J].2009,62(3).
- [14]Sun CC,Ramirez PT,Schmeler KM,etc.Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.[J].2008,108(3).
- [15]Schmeler, K. M.,Gershenson, D. M..Low-grade serous ovarian cancer: a unique disease[J].2008,10(6).